

## DAFTAR PUSTAKA

1. Kumar. Robbins Basic Pathology, 9th ed. Elsevier. 2012.
2. WHO 2013. Globocan, 2013. Int Agency Res Cancer, World Heal Organ. 2013;
3. Kemalasari DW, Nilapsari R, Rusmartini T. Korelasi Disfungsi Seksual dengan Usia dan Terapi pada Benign Prostatic Hyperplasia. Glob Med Heal Commun. 2017; Glob Med Heal Commun. 2017;
4. Lim K Bin. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol [Internet]. 2017;4(3):148–51. Available from:<http://dx.doi.org/10.1016/j.ajur.2017.06.004>
5. Filzha A. Gambaran Benigna prostat Hiperplasia di RSUP Prof. Dr. R. D. Kandou MAnado Periode Januari-Juli 2017. 2016;4(September 2015):127–31.
6. Mochtar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, Poernomo BB, et al. Pedoman penatalaksanaan klinis pembesaran prostat jinak (benign prostatic hyperplasia / BPH). In 2015. p. 1–27.
7. Manuscript A. NIH Public Access. 2012;82:220–36.
8. Gerber GS, Goldfischer ER, Karrison TG, Bales GT. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology.2015;
9. Loho IKA, Rambert GI, Wowor MF, Skripsi K, Kedokteran F, Sam U, et al. Gambaran kadar ureum pada pasien penyakit ginjal kronik stadium 5 non dialisis. 2016;4.
10. Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy (Seventh Edition). Lippincott Williams & Wilkins, a Wolters Kluwer business. 2014.
11. Mescher AL. Junqueira's Basic Histology: Text and Atlas, Thirteenth Edition. McGraw-Hill Education. 2013.

12. Sherwood L. Fisiologi Manusia dari Sel ke Sistem. Fisiologi Manusia dari Sel ke Sistem. 2013.
13. Purnomo BB. Urology in Asia - Indonesia. *Int J Urol*. 2011;
14. Nash J. Benign prostatic hyperplasia: risk factors and management. *Gerimed Midlife Beyond Urol*. 2011;
15. Banerjee PP, Banerjee S, Brown TR, Zirkin BR. Androgen action in prostate function and disease. *Am J Clin Exp Urol*. 2018;
16. Sampson N, Madersbacher S, Berger P. Pathophysiology and therapy of benign prostatic hyperplasia. *Wiener Klinische Wochenschrift*. 2012.
17. McAninch JW, Lue TF. *Smith & Tanagho's General Urology*. McGraw-Hill. 2013.
18. Roehrborn CG, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. *Campbell's Urol*. 2012;
19. Cannon GW, Getzenberg RH. Biomarkers for benign prostatic hyperplasia progression. *Curr Urol Rep*. 2013;
20. Verdiansah. Pemeriksaan Fungsi Ginjal. *J Diabetes*. 2016;Vol.43 No.(2):148–54.
21. Denise D. Wilson. *Manual of Laboratory and Diagnostic Test*. McGraw-Hill. United States; 2011.
22. Biddulth. Pemilihan Modalitas Pemeriksaan Radiologi untuk Diagnosis Benign Prostatic Hyperplasia. 2016;43 no. 6(6):471. Available from: <http://webcache.googleusercontent.com/search?q=cache:eEXBnbQQRNkJ:www.cdkjournal.com/index.php/CDK/article/download/75/72+&cd=1&hl=en&ct=clnk&gl=id&client=firefox-b-ab>
23. Kaplan SA. Identification of the patient with enlarged prostate: Diagnosis and guidelines for management. *Osteopath Med Prim Care*. 2011;1:1–6.

24. Hasbullah B. Angka Kejadian Komplikasi Lambat Pascaoperasi Prostatektomi Transvesikal dan Reseksi Transuretral pada Pasien Pembesaran Prostat Jinak. *Biomedika*. 20;1(1):1–5.
25. Issa MM, Thwaites D. Transurethral resection of the prostate (TURP). *Med Manag Surg Patient A Textb Perioper Med*. 2015;8:787–90.
26. Edlin R.S, Heyns C.F, Van V.S.P, Zarrabi A.D. Prevalence of Histological Prostatitis In Men With Benign Prostatic Hyperplasia or Adenocarcinoma of The Prostate Presenting Without Urinary Retention. 2012 Nov 12;50(4): 127-30
27. Kim wt, Yun sj, Choi yd Kim gy Mon sk, Choi yh, Kim iy, Jae kw. Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels. 2011 Sep 1; (9): 1214-1218)
28. Akdemir A.O, Oztekin C.V, Doluoglu O.G, Karabakan M, Ogulu O, Cetinkaya M. The Effect of Transuretral Resection of The Prostate on Morbidity and Mortality in Patient with Nondialysis-requiring Renal Insufficiency 2012 Apr;4(2):51-56